CTOs on the Move

Autism Family Center

www.autismfamilycenter.com

 
Autism Family Center fulfills a critical need for a coordinated, multidisciplinary approach to treating Autistic Disorder by providing a full range of services including Applied Behavior Analysis (ABA). Because we view families as an integrated system and believe that the health of every member is vital for each member to thrive, Autism Family Center provides support services for the entire family. Our process is designed to ensure maximum learning, unity and happiness.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Villa St. Francis

Villa St. Francis is a Catholic, non-profit skilled nursing facility that provides long term care, short term rehab, and skilled memory care for the frail and elderly, with special concern for the poor.

RIMMRI

RIMMRI is a East Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Craneville Place Of Dalton

Craneville Place Of Dalton is a Dalton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ryogen

Ryogen is a Suffern, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.